Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Autoimmune connective tissue diseases (ACTDs) are a family of consistent systemic autoimmune inflammatory disorders, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc) and Sjögren’s syndrome (SS). Toll-like receptors (TLRs) are located on various cellular membranes and sense exogenous and endogenous danger-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs), playing a critical role in innate immune responses. During the past decade, the investigation of TLRs in inflammation autoimmune diseases has been fruitful. In this report, we review the significant biochemical, physiological and pathological studies of the key functions of TLRs in ACTDs. Several proteins in the TLR signaling pathways (e.g., IKK-2 and MyD88) have been identified as potential therapeutic targets for the treatment of ACTDs. Antibodies, oligodeoxyribonucleotides (ODNs) and small molecular inhibitors (SMIs) have been tested to modulate TLR signaling. Some drug-like SMIs of TLR signaling, such as RDP58, ST2825, ML120B and PHA-408, have demonstrated remarkable potential, with promising safety and efficacy profiles, which should warrant further clinical investigation. Nonetheless, one should bear in mind that all TLRs exert both protective and pathogenic functions; the function of TLR4 in inflammatory bowel disease represents such an example. Therefore, an important aspect of TLR modulator development involves the identification of a balance between the suppression of disease-inducing inflammation, while retaining the beneficiary host immune response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947 · cited 1×
“…double-stranded RNAs (Alexopoulou et al., 2001; Brentano et al., 2005), TLR7 and TLR8 recognize single-stranded RNAs (Diebold et al., 2004; Heil et al., 2004; Vollmer et al., 2005) and TLR9 recognizes single-stranded DNA molecules containing hypomethylated CpG motifs (Hemmi et al., 2000;…”
BackgroundInnate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling
O'Neill, L. A. J., & Bowie, A. G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2079 · Cited by 2,667 · cited 1×
“…Toll/IL-1R (TIR) domain-containing adapter-inducing interferon-β (TRIF), TRIF-related adaptor molecule (TRAM) and sterile α- and armadillo motif-containing protein (SARM) are involved in the downstream signaling pathways of TLRs (O'Neill et al., 2003; O'Neill & Bowie, 2007; Roelofs et al., 2008).”
BackgroundPeptidoglycan- and Lipoteichoic Acid-induced Cell Activation Is Mediated by Toll-like Receptor 2
Schwandner, R., Dziarski, R., Wesche, H., Rothe, M., & Kirschning, C. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.25.17406 · Cited by 1,704
Epidemiology and estimated population burden of selected autoimmune diseases in the United States
Jacobson, D. L., Gange, S. J., Rose, N. R., & Graham, N. M. H. (1997) · Clinical Immunology and Immunopathology · doi:10.1006/clin.1997.4412 · Cited by 1,667 · cited 1×
“Possible causes of ACTDs include genetic (Romano et al., 2011; Chai et al., 2012), hormonal (Jacobson et al., 1997; Luppi, 2003) and environmental factors (Arnson et al., 2010); genetic factors may predispose an individual to the development of ACTDs.”
BackgroundNovel Signal Transduction Pathway Utilized by Extracellular HSP70
Asea, A., Rehli, M., Kabingu, E., Boch, J. A., Baré, O., Auron, P. E., Stevenson, M. A., & Calderwood, S. K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200497200 · Cited by 1,510
Oligosaccharides of Hyaluronan Activate Dendritic Cells via Toll-like Receptor 4
Termeer, C., Benedix, F., Sleeman, J., Fieber, C., Voith, U., Ahrens, T., Miyake, K., Freudenberg, M., Galanos, C., & Simon, J. C. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20001858 · Cited by 1,378 · cited 2×
“…that TLRs recognize and respond to endogenous ligands produced during infection or damage (Okamura et al., 2001; Smiley et al., 2001; Asea et al., 2002; Termeer et al., 2002; Vabulas et al., 2002; Park et al., 2004; Brentano et al., 2005; Vollmer et al., 2005; Yasuda et al., 2009) (Table 2).”
BackgroundToll-like receptors in systemic autoimmune disease
Marshak-Rothstein, A. (2006) · Nature Reviews Immunology · doi:10.1038/nri1957 · Cited by 1,116 · cited 1×
“TLR activation induces the production of pro-inflammatory factors and type I interferons, which contributes to the development and/or progression of systemic autoimmune diseases (Marshak-Rothstein, 2006).”
BackgroundChristensen, S. R., Shupe, J., Nickerson, K., Kashgarian, M., Flavell, R. A., & Shlomchik, M. J. (2006) · Immunity · doi:10.1016/j.immuni.2006.07.013 · Cited by 1,090
HMGB1 SIGNALS THROUGH TOLL-LIKE RECEPTOR (TLR) 4 AND TLR2
Yu, M., Wang, H., Ding, A., Golenbock, D. T., Latz, E., Czura, C. J., Fenton, M. J., Tracey, K. J., & Yang, H. (2006) · Shock · doi:10.1097/01.shk.0000225404.51320.82 · Cited by 832 · cited 5×
“TLR9 exerts a possible protective function against SLE, as demonstrated in various murine models of lupus (Lartigue et al., 2006; Wu & Peng, 2006; Yu et al., 2006b).”
BackgroundInfluential
Cited by
Microbiota in health and diseases
Hou, K., Wu, Z.-X., Chen, X.-Y., Wang, J.-Q., Zhang, D., Xiao, C., Zhu, D., Koya, J. B., Wei, L., Li, J., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00974-4 · Cited by 3,171
Self-citationTLR2 and TLR4 in Autoimmune Diseases: a Comprehensive Review
Liu, Y., Yin, H., Zhao, M., & Lu, Q. (2014) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-013-8402-y · Cited by 365
Self-citationSameer, A. S., & Nissar, S. (2021) · BioMed Research International · doi:10.1155/2021/1157023 · Cited by 323
Role of Microglia TLRs in Neurodegeneration
Fiebich, B. L., Batista, C. R. A., Saliba, S. W., Yousif, N. M., & de Oliveira, A. C. P. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00329 · Cited by 291
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
Gañán-Gómez, I., Wei, Y., Starczynowski, D. T., Colla, S., Yang, H., Cabrero-Calvo, M., Bohannan, Z. S., Verma, A., Steidl, U., & Garcia-Manero, G. (2015) · Leukemia · doi:10.1038/leu.2015.69 · Cited by 236
Metadata
- Authors
- Li, J., Wang, X., Zhang, F., & Yin, H.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 138
- Issue
- 3
- Pages
- 441-451
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2011337627
- Cited by
- 121
- References
- 17
- FWCI
- 6.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases. https://app.cochat.ai/papers/10.1016/j.pharmthera.2013.03.003
- The paper
- Li, J., Wang, X., Zhang, F., & Yin, H. (2013). Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases. Pharmacology & Therapeutics. https://doi.org/10.1016/j.pharmthera.2013.03.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.